The trademark application LELUNEVAY was filed by Eli Lilly and Company, a U.S. corporation (the "Applicant"). The application was published for oppositions on December 14, 2022, and it was registered by office on March 23, 2023 without any oppositions.
The application was filed in English (German was selected as the second language).
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and/or diagnosis of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and/or diagnosis of dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and/or diagnosis of migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and vascular diseases
Diagnostic agents, preparations and substances for medical purposes
Diagnostic scanning agents for medical use
Radiopharmaceutical diagnostic preparations for medical use